

Date: 22nd May 2023

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: Mankind

Dear Sir/ Madam,

Subject: Intimation of Board Meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company will be held on 30th May 2023, inter-alia to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023.

Further, in continuation of our earlier letter dated 9th May 2023 under subject 'Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for dealing in the securities of the Company shall remain closed upto 48 hours after the declaration of the Financial Results of the Company for the quarter and financial year ended on 31st March 2023.

The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com.

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Pradeep Chugh
Company Secretary and Compliance Officer
Membership No. A18711